Propeller Health

Propeller Health announced that it received FDA 510(k) clearance for connecting patients using its Symbicort Inhaler to its digital health platform.

The Madison, Wis.-based company’s digital health platform already connects to inhalers used by asthma and COPD patients, including ones manufactured by Boehringer Ingelheim, GlaxoSmithKline, Novartis and Orion, along with other generic equivalents.

Propeller’s digital health platform helps users with asthma or COPD manage their condition in tandem with their clinician by attaching sensors to existing inhalers to deliver insights on medication use to the Propeller app on their smartphone. Then, users can share insights with their clinician to help inform their treatment plan.

Clinical studies have revealed that the Propeller platform can increase asthma control by up to 63 percent, increase medication adherence by up to 58 percent, reduce asthma-related emergency department visits and hospitalizations b…

Propeller Health announced that it received FDA 510(k) clearance for connecting patients using its Symbicort Inhaler to its digital health platform.

The Madison, Wis.-based company’s digital health platform already connects to inhalers used by asthma and COPD patients, including ones manufactured by Boehringer Ingelheim, GlaxoSmithKline, Novartis and Orion, along with other generic equivalents.

Propeller sensors are designed to attach to existing inhalers and deliver insights on medication to the Propeller app on the user’s smartphone. The information delivered to the app can then be shared with clinicians to help inform treatment plans, according to a news release.

The company said its platform has shown in previous clinical studies to increase asthma control by up to 63% and increase medication adherence by up to 58%. It’s also shown to reduce asthma-related emergency department visits and hospitalizations by as much as 57% and reduce…